<DOC>
	<DOCNO>NCT02682459</DOCNO>
	<brief_summary>The natural course extracapillary glomerulonephritis severe lead End-Stage Renal Disease ( ESRD ) death case . Despite immunosuppressive treatment , long-term renal outcome remain poor since active crescent usually progress fibrotic scar glomerular occlusion disruption.In experimental model Angiotensin Converting Enzyme ( ACE ) -inhibitor therapy target over-expression angiotensin type 1 ( AT1 ) receptor , responsible dysregulated proliferation parietal cell progenitor , block formation crescent fibrotic evolution . Should drug similar effect human , ACE-inhibitor therapy top standard immunosuppression might instrumental prevent ESRD promote renal function recovery clinical practice .</brief_summary>
	<brief_title>ACE-inhibitors Extracapillary Glomerulonephritis</brief_title>
	<detailed_description />
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<criteria>Rapidly progressive renal failure associate acute nephritic syndrome and/or nephrotic syndrome ; Histology evidence extracapillary proliferation le 50 % sclerotic glomerulus associate : 1 . Type I : AntiGlomerular Basement Membrane ( GBM ) antibody glomerulonephritis , 2 . Type II : Pauciimmune vasculitis Anti Neutrophil Cytoplasmic Antibody ( ANCA ) associate vasculitis ; 3 . Type III : Immunecomplex mediate glomerular disease : Proliferative lupus nephritis ( LN ) , IgA nephropathy ( IgAN ) / Sch√∂nleinHenoch purpura , Type I membranoproliferative glomerulonephropathy ( MPGN ) , Primary secondary membranous nephropathy ( MN ) , Primary idiopathic immune complex glomerulonephritis . Clinical indication immunosuppressive therapy ; No specific indication treatment Renin Angiotensin System ( RAS ) inhibitor heart failure coronary ischemic disease ; Written inform consent . Preexisting advanced chronic renal failure ( creatinine clearance le 20 ml/min/1.73m2 ) ; Evidence B C virus active infection ; HIV infection ; Recent diagnosis malignancy ; Prolonged bleeding time contraindication kidney biopsy evaluation ; Any specific contraindication ACE inhibitor therapy ( : history angioedema treatmentrelated serious adverse event ) ; Pregnancy lactating ; Women childbearing potential without follow scientifically accept form contraception ; Inability understand risk benefit study evidence uncooperative attitude ; Legal incapacity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Extracapillary glomerulonephritis</keyword>
	<keyword>crescentic glomerulonephritis</keyword>
	<keyword>rapidly progressive renal failure</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>ACE-inhibitors</keyword>
	<keyword>fibrosis</keyword>
</DOC>